Skip to main content
OpenTrials
Completed

NCT Number: NCT03463707

BP101 for Adults With Female Sexual Dysfunction

This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD). Patients will be randomized in 1:1 ratio to either BP101 or placebo arms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypoactive Sexual Desire Disorder Female Sexual Dysfunction Mental Disorders Sexual Desire Disorder Sexual Dysfunctions, Psychological

Age range

21 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Алтайский государственный медицинский университет, Barnaul, Russia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged from 21 to 50 years old, who have signed informed concent, with a regular menstrual cycle (STRAW stages -5 to -3).
  • Decrease or loss of sexual desire (ICD-10 code: F-52.0) corresponding to the diagnosis of acquired generalized hypoactive sexual desire disorder (HSDD) according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM4), criteria.
  • Current HSDD episode lasting not less than 24 weeks.
  • Not less than 15 scores according to the FSDS-R (Distress) Total Score.
  • Stable monogamous relationship with one sexually active male sexual partner lasting at least a year. The partner is physically available not less than 50% of time during a month.
  • Consent to attempt to have a sexual intercourse at least twice a month, if she has a desire.
  • Consent to complete a diary every day during the screening period and assessment of the baseline state (in this period diary records must cover ≥80% days), during the therapy and subsequent follow-up.
  • Consent to use adequate methods of contraception throughout the study.

Exclusion criteria

  • Any prohibited treatments.
  • Other mental disorders or psychiatric diseases.
  • Diagnosed Decrease or loss of sexual desire (HSDD) is situational (reactive) or lifelong.
  • Score ≥ 20 according to the Beck Depression Inventory during the screening. Patients with 16 to 19 scores according to Beck's inventory may be included in the study unless, in the investigator's opinion, an actual depressive disorder is observed in the patient.
  • Inflammatory diseases of pelvic organs, infections of the genitourinary system, cervicitis, interstitial cystitis, vulvodynia or severe atrophy of the vaginal epithelium, precluding normal sexual activity.
  • Surgical interventions (other than cosmetic surgeries) on reproductive organs in past medical history (ovariectomy, hysterectomy, obvious scars from childbirth-related perineal stitches, etc), resulting in pain/dyspareunia, and/or precluding sexual contacts, and/or requires hormonal replacement treatment, and/or lead to the loss of sensibility while sexual contact.
  • Pregnant and nursing women or non-lactating women during the first 12 months after childbirth.
  • Consumption of more than 5 portions of alcoholic drinks per week or alcohol addiction, drug addiction or drug abuse in the past. One portion of an alcoholic drink means 360 ml of beer, 120 ml of wine or 30 ml of a strong alcoholic drink.

Treatment and study plan

BP101

Drug

Investigational product BP101, nasal spray

Placebo

Drug

Placebo to Investigational product BP101, nasal spray

Primary outcomes

  1. Satisfying sexual events

    Time frame: Baseline and 4 weeks of treatment

    Change in the number of satisfying sexual events (SSEs), standardized to the 28-day period, after 4 weeks of treatment, compared with the baseline.

Secondary outcomes

  1. Satisfying sexual events

    Time frame: Baseline and 4 and 8 weeks of follow-up

    Change in the number of satisfying sexual events (SSEs), standardized to the 28-day period, after 4 and 8 weeks of follow-up, compared with the baseline.

  2. Orgasms

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the number of orgasms, standardized to the 28-day period, after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

  3. Female Sexual Function Index total score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function Index (FSFI) total score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSFI total score ranges from 2.0 to 36.0, where higher score represents better sexual function. FSFI total score is a sum of FSFI individual domains scores (individual domains are: Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain).

  4. Female Sexual Function Index Desire domain score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function Index (FSFI) Desire domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSFI Desire domain score ranges from 1.2 to 6.0, where higher score represents better sexual desire.

  5. Female Sexual Function Index Arousal domain score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function Index (FSFI) Arousal domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSFI Arousal domain score ranges from 0 to 6.0, where higher score represents better sexual arousal.

  6. Female Sexual Function Index Lubrication domain score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function Index (FSFI) Lubrication domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSFI Lubrication domain score ranges from 0 to 6.0, where higher score represents better vaginal lubrication.

  7. Female Sexual Function Index Orgasm domain score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function Index (FSFI) Orgasm domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSFI Orgasm domain score ranges from 0 to 6.0, where higher score represents better orgasm sensation.

  8. Female Sexual Function Index Satisfaction domain score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function Index (FSFI) Satisfaction domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSFI Satisfaction domain score ranges from 0.8 to 6.0, where higher score represents better sexual satisfaction.

  9. Female Sexual Function Index Pain domain score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function Index (FSFI) Pain domain score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSFI Pain domain score ranges from 0 to 6.0, where higher score represents lower pain sensation during sexual intercourse.

  10. Female Sexual Distress Scale-Revised Total score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Distress Scale-Revised (FSDS-R) total score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSDS-R total score ranges from 0 to 52, where higher score represents higher level of distress related to sexual activities. A score of ≥11 discriminates between women with female sexual disfunction (score of ≥11) and no female sexual disfunction (score of <11).

  11. Female Sexual Distress Scale-Revised Item 13 score

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSDS-R Item 13 score ranges from 0 to 4, where higher score represents higher level of bother by low sexual desire.

  12. Sexual function according to the Female Sexual Function questionnaire

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    Change in the Female Sexual Function questionnaire (FSF) score after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

    FSF score ranges from 0 to 36, where higher score represents better sexual function.

  13. Patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement

    Time frame: Baseline and 4 weeks of treatment, 4 and 8 weeks of follow-up

    The patient's assessment of efficacy of the therapy according to the Patient Global Impression of Improvement (PGI-I) after 4 weeks of therapy and after 4 and 8 weeks of follow-up, compared with the baseline.

  14. Number of adverse events

    Time frame: During 12 weeks after start of treatment (4 weeks of treatment and 8 weeks of follow-up)

    Frequency of adverse events reporting, including serious adverse events, in treatment groups.

Sponsors and collaborators

Lead sponsor

Ivix LLX

Industry

Registry information

Official study title

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Confirmatory Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Important dates

Study start
2018
Primary completion
2018
Study completion
2019
First posted
Mar 13, 2018
Registry last updated
Feb 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.